Zephyrnet Logo

Generative Data Intelligence

Tag: product candidate

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe...

Medical Devices
ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide...

Top News

Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q | BioSpace

Medical Devices
FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the...

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference...

Medical Devices
50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone...

Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management |...

Medical Devices
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Direct MagnetOs sales grew to CHF 20.4 million in the first...

My Love/Hate Relationship with Process – LifeSciVC

Biotechnology
By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I remember vividly my first vacation with the man...

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

Clinical Trials
Treatment for: MucositisGalera Receives Complete Response Letter from U.S. FDA for Avasopasem ManganeseMALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq:...

Mithra Pharmaceuticals SA in €17m licencing deal

Biotechnology
Mithra and Searchlight Pharma  have inked a licensing deal for Donesta commercialisation in Canada. Donesta is the first Estetrol-based hormone substitution therapy...

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Biotechnology
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP enables localized, targeted delivery of CF33 to...

Latest Intelligence

spot_img
spot_img

Copyright @ 2024 Plato Technologies Inc.